Chemomab Therapeutics Ltd.

NasdaqCM CMMB

Chemomab Therapeutics Ltd. EBITDA for the year ending December 31, 2023: USD -25.39 M

Chemomab Therapeutics Ltd. EBITDA is USD -25.39 M for the year ending December 31, 2023, a 10.83% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Chemomab Therapeutics Ltd. EBITDA for the year ending December 31, 2022 was USD -28.48 M, a -130.88% change year over year.
Chemomab Therapeutics Ltd. EBITDA for the year ending December 31, 2021 was USD -12.33 M, a -107.35% change year over year.
Chemomab Therapeutics Ltd. EBITDA for the year ending December 31, 2020 was USD -5.95 M, a 77.91% change year over year.
Chemomab Therapeutics Ltd. EBITDA for the year ending December 31, 2019 was USD -26.92 M, a -101.54% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: CMMB

Chemomab Therapeutics Ltd.

CEO	Dr. Adi Mor George Ph.D.
IPO Date	Feb. 12, 2019
Location	Israel
Headquarters	Building 7
Employees	20
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Key trends

Past 5 years